BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DT-101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DT-101\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07610473-826@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:DT-101: Phase 2 readout est. (NCT07610473)
DESCRIPTION:DT-101\, phase 2\, Major Depressive Disorder.\nStudy: A Study t
 o Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patie
 nts With Depression\nEstimated primary completion: May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/dt-101#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07610473
URL:https://assetmemo.bio/drug/dt-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07300969-826@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:DT-101: Phase 2 readout est. (NCT07300969)
DESCRIPTION:DT-101\, phase 2\, Major Depressive Disorder.\nStudy: A Study t
 o Evaluate the Effectiveness of DT-101 in Patients With Depression\nEstima
 ted primary completion: August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dt-101#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07300969
URL:https://assetmemo.bio/drug/dt-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
